As of 2025-09-08, the Relative Valuation of Inhibikase Therapeutics Inc (IKT) is (5.88) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.67 USD, the upside of Inhibikase Therapeutics Inc based on Relative Valuation is -451.9%.
The range of the Relative Valuation is (4.79) - (7.52) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.6x - 13.6x | 11.1x |
| Forward P/E multiples | 6.5x - 13.5x | 10.0x |
| Fair Price | (4.79) - (7.52) | (5.88) |
| Upside | -386.8% - -550.2% | -451.9% |
| Date | P/E |
| 2025-09-05 | -3.00 |
| 2025-09-04 | -3.07 |
| 2025-09-03 | -3.11 |
| 2025-09-02 | -3.16 |
| 2025-08-29 | -3.23 |
| 2025-08-28 | -3.30 |
| 2025-08-27 | -3.21 |
| 2025-08-26 | -3.30 |
| 2025-08-25 | -3.16 |
| 2025-08-22 | -3.39 |
| 2025-08-21 | -3.02 |
| 2025-08-20 | -3.02 |
| 2025-08-19 | -3.05 |
| 2025-08-18 | -3.09 |
| 2025-08-15 | -3.14 |
| 2025-08-14 | -3.07 |
| 2025-08-13 | -3.07 |
| 2025-08-12 | -3.14 |
| 2025-08-11 | -2.71 |
| 2025-08-08 | -2.57 |
| 2025-08-07 | -2.78 |
| 2025-08-06 | -3.11 |
| 2025-08-05 | -3.23 |
| 2025-08-04 | -2.87 |
| 2025-08-01 | -2.73 |
| 2025-07-31 | -2.84 |
| 2025-07-30 | -2.96 |
| 2025-07-29 | -3.05 |
| 2025-07-28 | -3.18 |
| 2025-07-25 | -3.18 |
| 2025-07-24 | -3.32 |
| 2025-07-23 | -3.55 |
| 2025-07-22 | -3.47 |
| 2025-07-21 | -3.38 |
| 2025-07-18 | -3.30 |
| 2025-07-17 | -3.41 |
| 2025-07-16 | -3.34 |
| 2025-07-15 | -3.23 |
| 2025-07-14 | -3.48 |
| 2025-07-11 | -3.32 |
| 2025-07-10 | -3.59 |
| 2025-07-09 | -3.63 |
| 2025-07-08 | -3.61 |
| 2025-07-07 | -3.47 |
| 2025-07-03 | -3.39 |
| 2025-07-02 | -3.32 |
| 2025-07-01 | -3.50 |
| 2025-06-30 | -3.50 |
| 2025-06-27 | -2.91 |
| 2025-06-26 | -2.96 |